A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Conditions: Oncology; MEK Mutation; RAF Gene Mutation; Ras (KRAS or NRAS) Gene Mutation; Melanoma; NSCLC; Glioma; Solid Tumor, Adult; MAPK Pathway Gene Mutation Interventions: Drug: NST-628 Sponsors: Nested Therapeutics, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain Tumor | Cancer & Oncology | Genetics | Glioma | Melanoma | Non-Small Cell Lung Cancer | Research | Skin Cancer | Study